Campbell David Alan 4
4 · Janux Therapeutics, Inc. · Filed Nov 27, 2024
Insider Transaction Report
Form 4
Campbell David Alan
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-11-25$52.04/sh−6,719$349,647→ 257,054 total - Sale
Common Stock
2024-11-25$51.43/sh−18,281$940,232→ 263,773 total
Footnotes (3)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 21, 2024.
- [F2]The weighted average sale price for the transaction reported was $51.4322 and the range of prices were between $50.89 and $51.885. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $52.0385 and the range of prices were between $51.89 and $52.385. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.